Rishi Sunak calls for national prostate cancer screening
In his first major intervention since standing down as prime minister, Mr Sunak calls for targeted screening, so those with higher risk of the disease such as those with a family history of it undergo checks.
The UK National Screening Committee (UK NSC) is currently considering whether to roll out screening.
Experts believe there is a growing case for targeted screening, meaning that PSA blood tests would be offered to those at heightened risk of the disease.
Writing for The Telegraph, Mr Sunak urges the UK NSC to make the leap – and to do so 'without delay'.
In the meantime, he urges all men to use Father's Day this Sunday as an opportunity to talk to their fathers about their health.
The MP, who recently became an ambassador for charity Prostate Cancer Research, writes: 'On Father's Day, many of us will call our dads for a chat. We'll discuss many things: the news, sport, the family. But few of us will touch on our health.
'For we men aren't very good at addressing that: I am the son of a GP but even me and my dad don't talk enough about health. In fact he's had a test, but it took him a while to get round to it. It's not that the topic is taboo, more that it never seems quite the right moment to ask a delicate question.
'But talking about health with your dad, and particularly the misconceptions around prostate cancer, could save their life. It is one of the best things you could do this Father's Day, and a true act of love'.
Although one in eight men will be diagnosed with prostate cancer in their lifetimes, polling has found only 7 per cent of men know that the disease is symptomless in its early stages.
Mr Sunak warns too many men were leaving it 'dangerously late' to seek help, only coming forward when symptoms such as pain or blood in urine began to show.
He says: 'The cancer will almost certainly be advanced at this point, and treatment far less certain to succeed. This ignorance is costing lives. It is why we need a targeted national screening programme to make sure that the right men are being checked at the right time for the disease. If we can make this happen, we can save thousands of lives.'
Mr Sunak adds that since becoming an ambassador for the charity: 'What has really struck me in this time is how alien it is for men to proactively ask to be checked for a disease. Our assumption is that if everything is working fine, it is fine.
'When I raise prostate cancer and the need to get checked, men regularly tell me that everything is functioning down there, so they don't need a test. But that is not right: and this confusion is costing lives.'
The UK NSC is expected to make a decision by the end of this year.
Its members are considering different models, with discussions about the definition of close relatives if a family history becomes part of the criteria for targeted screening.
As well as family history, risk factors also include ethnic group – with one in four black men diagnosed with the disease.
Many experts in prostate cancer are calling for the 'dangerous' guidelines to be changed, so that younger men with a family history of prostate cancer such as Sir Chris Hoy can be tested for the disease.
The 49-year-old, who is a six-time Olympic cycling gold medallist, was told he has two to four years to live after being diagnosed with terminal cancer that originated in his prostate.
Despite a family history of prostate cancer – which affected both his father and grandfather – he was never offered PSA tests.
In the UK prostate cancer is the most common cancer in men, with over 55,000 new cases diagnosed annually. Cases have risen by one quarter in the last five years.
Despite improvements in survival, over 12,000 men die from prostate cancer each year.
If prostate cancer is caught early, the chances of successful treatment are far higher. If it is detected after the disease has spread, the success rate of treatment is below 50 per cent.
Mr Sunak salutes the work of men who have spoken out about the need to get checked, saying his friend Joe Biden's diagnosis would also raise awareness.
Credit: US Network Pool via Reuters
Oliver Kemp, chief executive of Prostate Cancer Research, said the rollout of targeted screening would prevent 300 men a year from developing incurable disease.
He said: 'Every 40 minutes in the UK, a family loses a father, a grandfather, or a son to prostate cancer. This is a tragedy compounded by a postcode lottery that means a man's chances of survival can depend on where he lives.
'The current passive system, where men must know their own risk and ask for a test, is failing us and worsening health inequality across the UK. That is why Prostate Cancer Research is calling for the urgent introduction of a targeted national screening programme for men at the highest risk, including black men and those with a family history of the disease'.
Polling has found 94 per cent of GPs would back the rollout.
Mr Kemp said: 'As the UK National Screening Committee finalises its review, we call on the Government to champion this life-saving reform, which aligns perfectly with their stated mission to prioritise prevention and tackle health disparities. The time for waiting is over; the lives of thousands of men depend on this decision.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
8 liver-friendly foods to add to your diet, as majority of cancer cases preventable
Want to look after your liver better? These eight foods could help. We all know the importance of eating healthily for our heart, gut, and brain – but there are some foods that are especially beneficial for your liver health, too. Despite the liver's status as a vital organ that performs a number of important bodily functions, including removing toxins and fighting infection, it's easy to forget about looking after it. But recent statistics highlight the importance of prioritising your liver health. Experts say that three in five liver cancer cases "are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity", but have raised concerns that cases caused by alcohol and obesity will increase in the coming years. According to The Telegraph, scientists predict that, by 2050, around 21% of liver cancers will be caused by alcohol and 11% will be caused by a severe form of fatty liver disease, which occurs when excessive fat builds up in the vital organ. Last year, analysis by Cancer Research UK revealed that the number of people dying from liver cancer had almost doubled in the last 20 years. The disease is now responsible for the deaths of 58,000 people in the UK each year, twice the rate recorded in the late 1990s. Cancer Research UK said the figure is projected to continue rising by a further 10% by 2040, warning that liver cancer will have killed around 135,000 people by then. While part of the rise in deaths has been driven by a growing British population, lifestyle factors also play a major role. Katrina Brown, senior statistics manager at Cancer Research UK, told The Independent that around half of all cases are preventable. Drinking alcohol and smoking are key drivers of the increasing number of cases, as well as being overweight or obese. Brown added: "The notable thing for liver cancer is overweight and obesity is a key risk factor, and that has been steadily increasing in the UK – around two-thirds of UK adults are overweight and obese." The number of people who have died with an underlying cause of liver disease in England has also risen in recent years. According to the Department of Health and Social Care (DHSC), this figure rose to 10,127 from 9,218 in 2019, increasing further to 10,521 cases in 2021. Eating a healthy, well-balanced diet is important to protect your liver and keep it in good shape for longer. Certain foods have been found to enhance liver function, while others can help prevent or reverse liver damage, according to various studies. Here are eight liver-friendly foods to incorporate into your daily diet: 1. Leafy greens Leafy greens like spinach and kale are rich in antioxidants, vitamins and minerals, which can help protect the liver from oxidative damage. A 2019 study found that the chlorophyll in leafy greens also have detoxifying properties, which can help reduce liver toxicity. 2. Garlic While the phrase 'there's no such thing as too much garlic' may not be strictly true, eating garlic does come with health benefits. Garlic contains sulfur compounds that improve liver enzyme activity, as well as anti-inflammatory and antioxidant properties, which can reduce oxidative stress in people with non-alcoholic fatty liver disease, one study suggested. 3. Beetroot Bright red beetroot is known to help with high blood pressure, as it's rich with dietary nitrates. This root vegetable also contains betalains, a type of antioxidant, and compounds that may support liver detoxification by increasing the liver's production of detoxifying enzymes. 4. Turmeric Curcumin, the active compound in turmeric, has strong anti-inflammatory and antioxidant properties. A clinical trial published in the journal Hepatology showed that curcumin supplementation reduced liver inflammation in patients with non-alcoholic fatty liver disease. 5. Green tea A 2006 study, published in the International Journal of Molecular Medicine found that green tea extract improved liver function and reduced fat accumulation in the organ. This is believed to be thanks to the antioxidants called catechins that green tea is rich in. 6. Cruciferous vegetables Cruciferous vegetables refer to vegetables like broccoli, Brussels sprouts and cauliflower. They are rich in fibre and vitamins, as well as glucosinolates, which researchers believe stimulate the production of detoxifying enzymes in the liver and protect against oxidative damage. 7. Lentils and beans Experts often sing the praises of lentils and beans as a nutritious source of fibre and protein that is suitable for vegetarians and vegans. But that's not all – the high fibre content in lentils and beans can contribute to helping reduce liver fat accumulation and improving liver function. 8. Artichokes Researchers published a study in Phytotherapy Research that found artichoke extract, which contains cynarin, can aid in improving liver function. Cynarin is a compound known to stimulate bile production, which can helps with the detoxification process and protects liver cells. Read more about diet and nutrition: I'm a nutritionist on a budget and here's how I get my five-a-day for much less (Yahoo Life UK, 6-min read) 9 cheap, healthy and easy meal ideas with less than 6 ingredients (Yahoo Life UK, 9-min read) 5 ultra-processed foods you shouldn't stop eating (Yahoo Life UK, 5-min read)
Medscape
6 days ago
- Medscape
Family History Shapes Psoriatic Disease Onset in PsA
TOPLINE: Patients with psoriatic arthritis (PsA) who had a family history of psoriatic disease were diagnosed with psoriasis and PsA earlier and showed more entheseal involvement than those without such family history. METHODOLOGY: Researchers enrolled 843 patients with PsA (mean age, 50.8 years; 50.6% men; 76.4% White individuals) from the New York University (NYU) Psoriatic Arthritis Center and associated clinics in an observational, longitudinal registry to study familial aggregation and differences in disease onset and phenotype. They collected data on demographics, medical and family history, and psoriatic phenotype and activity. Patients were categorized on the basis of family history, with 379 participants having one or more first-degree or second-degree relatives with psoriatic disease (301 had relatives with psoriasis, and 78 had relatives with PsA) and 464 having no history. Disease measures included the age at which psoriasis and PsA were diagnosed, types and locations of psoriasis, and areas affected by PsA. TAKEAWAY: Patients with a family history of psoriatic disease were diagnosed with psoriasis and PsA earlier than those without (mean age, 27.6 vs 32.2 years and 37.6 vs 40.3 years, respectively; P < .01 for both). Patients with first-degree or second-degree relatives with PsA were diagnosed with psoriasis and PsA earlier than those with relatives with psoriasis alone or no family history (P < .01 and P = .01, respectively). Patients with a family history of psoriatic disease were more likely to have a history of enthesitis than those without (36.7% vs 30.0%; P < .05) and active enthesitis at baseline (30.1% vs 21.6%; P < .01). The transition time between the diagnosis of psoriasis and PsA was longer among patients with two or more first-degree or second-degree relatives than among those with only one relative or those with no family history (mean time to diagnosis, 14.1 vs 8.0 vs 8.8 years; P < .01). IN PRACTICE: 'Additional studies integrating molecular and immune features are needed to elucidate how genetic, environmental, and epigenetic elements influence the progression from psoriasis to PsA, as well as PsA's clinical presentation, severity, and therapeutic response,' the authors of the study wrote. SOURCE: The study was led by Catherine Howe, MD, NYU Grossman School of Medicine, New York City. It was published online on July 14, 2025, in Arthritis & Rheumatology. LIMITATIONS: The study relied on patient-reported data for age of diagnosis and family history, which may introduce potential recall bias and underdiagnosis of mild cases. Having a family history may not equate to genetic burden. The lack of a uniform baseline visit for all patients with PsA may affect the assessment of disease activity. DISCLOSURES: This study was funded by grants to authors from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the NYU Colton Center for Autoimmunity, the Rheumatology Research Foundation, the National Psoriasis Foundation, and other sources. Two authors reported receiving support from an Institutional National Research Service Award and the National Institute of Diabetes and Digestive and Kidney Diseases. Some authors reported receiving consulting fees from or serving on advisory boards for pharmaceutical companies that market drugs for psoriatic disease. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
22-07-2025
- Medscape
Role of GLP-1 Drugs in Psoriasis and PsA Is Debated
BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss drugs, have the potential to help some patients with psoriasis and psoriatic arthritis (PsA). Besides mitigating obesity, an established risk factor for psoriasis and PsA, GLP-1 drugs have shown promise in improving psoriasis symptoms and are associated with a lower risk for cardiovascular events, for which people with psoriasis and PsA are at increased risk. Some researchers predict that the drugs will prove to have immunomodulatory effects and become an important addition to current treatments for psoriasis and PsA, even in patients without obesity or diabetes. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, investigators with the GRAPPA dove into hours' worth of discussions and debates about a class of drugs whose emergence Artie Kavanaugh, MD, professor of medicine at the University of California, San Diego, described as a possible 'watershed moment' for the field, akin to the advent of biologic therapies in the 1990s. But with evidence still sparse in patients with psoriatic disease and ancillary concerns about access, cost, patient selection, and physician confidence in prescribing, there was little agreement as to how, whether, or when these drugs should be integrated into clinical practice. A GLP-1 Pioneer Endocrinologist Daniel J. Drucker, MD, professor in the Department of Medicine's Division of Endocrinology, University of Toronto, Ontario, Canada, who discovered some key biological actions of the hormone GLP-1 in the 1980s and '90s, kicked off the conference with a video presentation affirming GLP-1 RAs potential as immunoregulatory agents with anti-inflammatory activity beyond their well-documented effects on body weight. In a 2023 trial of semaglutide in patients with obesity who did not have diabetes, Drucker noted prevention of cardiovascular events and death was seen as independent of weight loss. Similarly, Drucker said, a recent trial in people with metabolic liver disease saw improvements associated with semaglutide that were independent of weight loss. With psoriasis and PsA, randomized controlled trial evidence has yet to support weight-loss independent improvements in symptoms. However, this may soon change: In two separate trials, Eli Lilly is studying a combination of tirzepatide and the interleukin-17A antagonist ixekizumab in patients with overweight or obesity and psoriasis or PsA. The trials will wrap up next summer. Results from trials of GLP-1 inhibitors in nonobese populations, including cohorts of people with Alzheimer's disease, stand to shed further light on their anti-inflammatory effects outside the context of weight loss, Drucker said. 'These medicines are diversifying. We're going to see a wave of new molecules and new indications to treat inflammation,' he predicted, including that of skin, joints, and bone. Still, Drucker cautioned, the drugs 'are not magic bullets, and each condition will need to be assessed on its own.' Real-World Experience From Latin America In a subsequent talk, Enrique Soriano, MD, head of rheumatology at the Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, presented a real-world perspective from Latin America, where GLP-1 drugs are approved in most countries for diabetes or obesity — but still not easy to access and far from becoming a routine part of any rheumatologist's or dermatologist's daily practice. 'We all know that obesity increases the risk of developing psoriatic arthritis in psoriasis patients,' Soriano said — and that weight loss can decrease that risk. 'We also know that treatment response is lower in PsA patients with obesity,' he said. 'But the question for us is whether this drug [class] can improve symptoms and inflammation in our patients and whether this improvement, if it happens, is related to the weight loss or is an independent effect.' Soriano presented a retrospective review from his institution's service of 6800 patients with psoriasis (mostly mild) and 488 with PsA. In each group, just over 1% of patients were taking a GLP-1 RA for obesity, diabetes, or both. While acknowledging the limitations of his study's retrospective design, Soriano noted that 'there was no report of any improvement or change in the skin involvement, and there was also no record of any change in their joint symptoms after starting these drugs.' Soriano also conducted a survey of rheumatologists across several countries in Latin America and found that under a third said that they had encountered a patient whom they thought could benefit from the addition of a GLP-1 drug, while fewer than 10% said that they would feel confident prescribing one. More than half said that if they did think a patient could benefit, they would refer that person to a specialist, such as an endocrinologist. Dermatologist Describes Current Data as 'Weak' Anthony Fernandez, MD, PhD, director of medical and inpatient dermatology at the Cleveland Clinic, Cleveland, praised GLP-1 RAs as 'fascinating medications' with 'a very attractive adverse event profile.' Fernandez cited studies dating back over a decade in which use of these medications has been shown to improve psoriasis. 'And we have some data to suggest that the mechanism…is not entirely related to weight loss. In fact, there's data to support that these medications affect psoriasis-relevant immune pathways. So, in that way, they share similarities with many of the systemic medicines that we already prescribe to treat psoriasis.' Still, Fernandez cautioned, 'The data right now is really weak,' limited to small studies and randomized trials enrolling mostly men. While a few patients in these studies saw dramatic improvements in psoriasis after starting these drugs, 'the reality is that most have, at best, a modest improvement,' he said, 'certainly nowhere near the improvement we are used to seeing' from targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs). Moreover, he said, some patients enrolled in the studies were effectively treatment naive. 'That raises a critical question about whether or not a patient [on ts- or bDMARDs] would actually see any further improvement adding GLP-1 RAs,' he said. Fernandez said he thought that dermatologists can safely prescribe and manage GLP-1 therapies. The bigger question is whether they should. 'My opinion is no,' he concluded. 'There will be rare patients who are obese and or have type 2 diabetes and either fail or have a contraindication to all the great systemic medicines we already have available to us. And in those patients, a trial of a GLP-1 RA would seem to be reasonable. But personally, I think we need much, much better data for recommendations concerning general use by dermatologists.' During a question-and-answer period after Soriano's and Fernandez's presentations, other physicians shared their experiences and practical concerns about insurance approvals, referrals, and whether most dermatologists and rheumatologists were simply too busy to manage all the comorbidities of chronic immune-mediated disease for their patients. Some shared anecdotes about patients whose disease had improved after treatment with GLP-1 RAs, including in the absence of other systemic therapies. Patients Intrigued — but Share Clinician's Caution At the same session, Suzanne Grieb, PhD, a patient research participant (PRP) with GRAPPA and assistant professor at Johns Hopkins University, Baltimore , presented results from a survey of her fellow GRAPPA PRPs about their experiences and interests regarding GLP-1 drugs. None of the 11 respondents reported having been prescribed the medications. 'The majority of us described our psoriatic disease as mostly manageable with our current treatment,' Grieb, who has PsA, told the conference. However, that did not mean they weren't curious about GLP-1s. Grieb's survey revealed that while all participants were aware of the importance of exercise and healthy weight in disease management, many continued to struggle with both. Few reported having spoken with their providers about specific interventions. While three respondents expressed interest in taking GLP-1s, they were uncertain whether they would be able to access them. Patients 'are interested in GLP-1s' impact on our psoriatic disease, but also on other elements of our health, thinking more holistically [about] the benefits that could be achieved through these medications,' Grieb said. But the respondents in her survey also reported concerns about adding medications and 'the potential for having to take this medication for the rest of our lives.' In an interview after her presentation, Grieb elaborated on her personal perspective. 'I don't meet the requirement for obesity,' she said. 'But I'm overweight, and I could probably benefit from a GLP-1. Without clear weight-related indications, it's hard, perhaps to be able to justify prescribing it if it's not going to be available. So it's a hard conversation [for clinicians] to bring up with their patients.'
